ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / SLBT / dividends
SLDB (26) FDMT (44) ATTO (44) CADL (33) ⌘ Pro Terminal →

SL Science Holding Limited (SLBT) Dividend Safety Gauge & 10-Year DRIP Compounder

$1.27 +5.83% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.28

SL Science Holding Limited (SLBT) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $672.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SLBT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SLBT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, SL Science Holding Limited (NASDAQ: SLBT) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $1.27 (+5.83% 1D, market cap $672.9M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, SLBT ranks #364 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SLBT compare to SLDB and FDMT in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SLBT carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SLDB (Solid Biosciences Inc.) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $664.8M) and FDMT (4D Molecular Therapeutics Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -28.3%, cap $657.4M). Among the 5-stock peer group, SLBT leads on earnings multiple (N/A) while FDMT leads on capital efficiency (-28.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SLBT?
▼

Per SLBT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002070534), SL Science Holding Limited generated $4.9K in revenue, $0 in net income, and $0 in free cash flow against $11.8K in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.28 (+0.86%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 1884.2% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510045
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Cash (10)Whales (3)SEC (13)Macro (10)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-5.5% Base Target
$15 Bull$1 Base$1 Bear
📬 FREE SLBT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SLBT)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (45/100 Composite)
🔍 WHY SLBT SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 1884.2% FCF Margin ($18.8M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
53
Grade C-$1.53-2% Next Q
Q2 (-2Q)
50
Grade C-$1.50-18% Next Q
Q3 (-1Q)
48
Grade D$1.23+3.3% Next Q
Current
45
Grade D$1.27-6.3% Hist 90D α
Trajectory: C- (53) → D (45)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SLBT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SLBT currently carries a cautious 45/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.83) and Max Pain ($1.33) forces dealer call-delta covering toward $15.23.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SLBT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SLBT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 45%NO 55%Trade / Inspect Odds →
CASH DIVIDEND + BUYBACK YIELD
1.8% Total Yield
0% Cash ($0.00/yr) + 1.8% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 • REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr
$10.7K
Yr 1
$11.4K
Yr 2
$12.2K
Yr 3
$13.0K
Yr 4
$13.9K
Yr 5
$14.8K
Yr 6
$15.8K
Yr 7
$16.9K
Yr 8
$18.1K
Yr 9
$19.3K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SLBT)

  • ✓Walkthrough of SLBT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
SLBT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -85.08%▲ RESISTANCE BREAKOUT
2026-11-03O $1.17H $1.27L $1.17C $1.27VOL 26.6K
RES: $1.07SUP: $0.87SMA50: $1.83SMA200: $6.00
$15.44$11.53$7.63$3.72$-0.19RES $1.07SUP $0.87$1.272026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SLBT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SLBT Butterfly Map → + Track SLBT →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SLBT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SLBT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SLBT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SLBT)

Health Care Rank #364 of 1015 ⚔️ SLDB vs SLBT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SLBT vs. SLDB, FDMT, ATTO, CADL)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, SL Science Holding Limited (SLBT) ranks #364 by composite RQD confidence (45/100, grade D) and #398 by equity capitalization ($672.9M). Within this direct 5-issuer industry benchmark cohort, SLBT leads on earnings valuation at N/A trailing P/E, while FDMT leads on capital efficiency and profitability with -28.3% ROIC and — gross margin. SLBT currently leads its immediate peer cohort in composite quantitative strength at 45/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SLBT ACTIVE
SL Science Holding Limited
D 45/100 — — — +5.83% $672.9M Benchmark Subject
SLDB
Solid Biosciences Inc.
E 26/100 — — -35.0% -3.23% $664.8M /sldb-vs-slbt →
FDMT
4D Molecular Therapeutics Inc.
D 44/100 — — -28.3% -4.45% $657.4M /fdmt-vs-slbt →
ATTO
Attovia Therapeutics Inc.
D 44/100 — — — -0.92% $693.4M /atto-vs-slbt →
CADL
Candel Therapeutics Inc.
E 33/100 — — -35.0% -2.52% $637.4M /cadl-vs-slbt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002070534 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), SL Science Holding Limited (SLBT) reported GAAP revenue of $4.9K , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, SLBT closed FY2025 with $11.8K in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $4.9K $0 — — $11.8K —

3. SLBT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SLBT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, SL Science Holding Limited (NASDAQ: SLBT) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $1.27 (+5.83% 1D, market cap $672.9M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, SLBT ranks #364 in composite RQD confidence.

How does SLBT compare to SLDB and FDMT in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SLBT carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SLDB (Solid Biosciences Inc.) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $664.8M) and FDMT (4D Molecular Therapeutics Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -28.3%, cap $657.4M). Among the 5-stock peer group, SLBT leads on earnings multiple (N/A) while FDMT leads on capital efficiency (-28.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SLBT?

Per SLBT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002070534), SL Science Holding Limited generated $4.9K in revenue, $0 in net income, and $0 in free cash flow against $11.8K in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SLBT trading relative to its 50-day, 200-day, and 52-week technical levels?

SLBT last traded at $1.27 (+5.83% on volume of 15,619 shares), positioning the stock -30.60% below its 50-day simple moving average ($1.83) and -78.83% below its 200-day simple moving average ($6.00). Across its 52-week range of $1.02 to $14.50, SLBT sits at the 1.9% percentile with a 14-day RSI of 30.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.11 to $1.43).

Direct Sub-Reports: SLBT RQD Cockpit SLBT 12M Forecast SLBT Earnings & Move SLBT Dividends & DRIP SLBT Insiders & 13F SLBT Whale Options SLBT Profit Sankey SLBT News & Why
ROARABLE RATING BRIEF • RQD 45/100 (D) ✓ SEC XBRL & RQD VERIFIED

SLBT — SL Science Holding Limited: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

SL Science Holding Limited (SLBT) earns a live Roarable RQD composite score of 45/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $1.27 (+5.83% 1D, market capitalization $672.9M).

  • Fundamental Cash Engine (10/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

SL Science Holding Limited (SLBT) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry..7B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), SL Science Holding Limited (SLBT) reported $4.9K in annual revenue and $0 in GAAP net income. Operating cash flow reached $0 and free cash flow totaled $0, backed by $11.8K in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 45/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 10/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.02 – $14.50 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies cannot be identified from source data. Sector classification is Health Care and industry is Biotechnology: Biological Products (No Diagnostic Substances); no sector correlation data is provided. Second-order bottlenecks cannot be assessed from source data.

  • Key Question #1: Can SLBT sustain or expand its — operating margin and — ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $4.9K and free cash flow of $0, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is SLBT's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SLBT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for SL Science Holding Limited (SLBT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SLBT Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SLBT Bull vs. Bear Conversation Board — What's Your Call at $1.27?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SLBT 🐻 33% BEARISH CONVICTION
1. Pick Your Side on SLBT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $1.55 (+29.2%)
📌 Pinned Debate

The forensic balance sheet pillar is the strongest component at 13 / 20, with an Altman Z of 2.5 and a Piotroski F of 6/9.

The street is overcomplicating SL Science Holding Limited (SLBT). The forensic balance sheet pillar is the strongest component at 13 / 20, with an Altman Z of 2.5 and a Piotroski F of 6/9.. With an RQD score of 45/100 (D) and Forensic Balance Sheet at 13/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $1.30.

VolSurface_Trader 🐂 BULL

@SkepticalCFA Shorting a 3/20 institutional whale-flow stock at $1.20 is dangerous when funds are rotating into Health Care.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $0.95 (-20.8%)
Spot @ $1.20

The company reports zero revenue, zero net income, and 0% ROIC and FCF yield, while the stock trades at $1.17 versus a 52-week high of

Sitting on the sidelines or leaning short SLBT above $1.20. The company reports zero revenue, zero net income, and 0% ROIC and FCF yield, while the stock trades at $1.17 versus a 52-week high of $14.5.. Until Fundamental Cash Engine (10/20) and FCF yield (0.0%) inflect higher, upside is capped near $14.50.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%